G1 Therapeutics Inc.
http://www.g1therapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From G1 Therapeutics Inc.
Keeping Track: Cloudy Horizon For Teplizumab, Roxadustat; Nuplazid Stumbles Over Subgroups; CAR-T Submissions From Gilead, J&J
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
FDA Perturbed By Provention's Teplizumab Type 1 Diabetes Drug
The US regulator is worried about deficiencies in the submission for Provention Bio’s high-profile therapy teplizumab for the prevention of type 1 diabetes that could significantly delay its review.
Keeping Track: US FDA Acts On 5 Novel Drugs: Approval For Fotivda, Pepaxto, Azstarys; CRLs For Defencath and Oral Paclitaxel
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Keeping Track: Regeneron Wins US FDA OK For Evkeeza, New Libtayo Uses; G1 Cosela Cleared
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Biotechnology
- Pharmaceuticals